Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/12/2019
SIETES contiene 92856 citas

 
 
 1 a 20 de 101 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Blanco-Silvente L, Castells X, Garre-Olmo J, Vilalta-Franch J, Saez M, Barceló MA, Capellà D. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103212]
2.Enlace a cita original Cita con resumen
Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]
3. Cita con resumen
Obach M, Lopez P, Catalan A. Tratamiento farmacológico de la enfermedad de Alzheimer en la población de Catalu˜na. Med Clin (Barc) 2017;149:86-7. [Ref.ID 101905]
4.Enlace a cita original Cita con resumen
Bellostas Umbert JM, Carnero Pardo DC, García Lirola MA. Enfermedad de Alzheimer: tratamiento farmacológico. Boletín Terapéutico Andaluz 2014;29:1-9. [Ref.ID 98102]
5. Cita con resumen
Anónimo. Prescribing drugs for Alzheimer's disease in primary care: managing cognitive symptoms. Drug Ther Bull 2014;52:69-72. [Ref.ID 97708]
9. Cita con resumen
Tricco AC, Soobiah C, Berliner S, Ho JM, Ng CH, Ashoor HM, Chen MH, Hemmelgarn B, Straus SE. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. Can Med Assoc J 2013;185:1393-401. [Ref.ID 96118]
10. Cita con resumen
Anónimo. No hay medicamentos "para toda la vida". Infac: Información Farmacoterapéutica de la Comarca 2013;21:10-7. [Ref.ID 95240]
11. Cita con resumen
Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 2012;344:43-7. [Ref.ID 92853]
12. Cita con resumen
Boudreau DM, Yu O, Gray SL, Raebel MA, Johnson J, Larson EB. Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. J Am Geriatr Soc 2011;59:2069-76. [Ref.ID 91576]
13. Cita con resumen
Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc 2011;59:1019-31. [Ref.ID 90768]
14.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377:1019-31. [Ref.ID 90421]
15. Cita con resumen
Anónimo. NICE recommends Alzheimer's drugs for mild disease. BMJ 2011;342:678. [Ref.ID 90340]
16.Tiene citas relacionadas
van Eijk MM, van Gool W, Slooter AJC. Cholinesterase inhibitor treatment in patients with delirium. Authors' reply. Lancet 2011;377:901. [Ref.ID 90324]
17.Tiene citas relacionadas
Opdam FL, Oleksik AM, Westendorp RGJ. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:900-1. [Ref.ID 90323]
18.Tiene citas relacionadas
Berg RMG, Moller K. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:900. [Ref.ID 90322]
19.Tiene citas relacionadas
Gusmao-Flores D, Chalhub RA, Quarantini LC. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:899-900. [Ref.ID 90321]
20.Tiene citas relacionadas
de Pont A-CJM, van Geer MA. Cholinesterase inhibitor treatment in patients with delirium. Lancet 2011;377:899. [Ref.ID 90320]
Seleccionar todas
 
 1 a 20 de 101 siguiente >>